Oppenheimer Holdings Weighs in on Exelixis, Inc.'s Q3 2017 Earnings (EXEL)

Oppenheimer Holdings Weighs in on Exelixis, Inc.'s Q3 2017 Earnings (EXEL)

Oppenheimer Holdings Weighs in on Exelixis, Inc.'s Q3 2017 Earnings (EXEL)

On Tuesday, Shares of Exelixis, Inc. Moreover, Exelixis is developing cabozantinib in a broad development program and plans to file a supplemental New Drug Application (sNDA) in the third quarter of 2017 for advanced RCC. Cann started coverage on Exelixis in a report on Wednesday, March 15th. Acrospire Investment Management LLC boosted its stake in Exelixis by 7.2% in the third quarter. They now have a United States dollars 4 price target on the stock. Oppenheimer Holdings Inc. restated a "market perform" rating on shares of Exelixis in a research note on Friday, April 21st. The biotechnology company reported $0.05 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.01) by $0.06.

Several research analysts have recently commented on EXEL shares.

The company has a 50 day moving average price of $21.38 and a 200-day moving average price of $18.34. Exelixis now has an average rating of "Buy" and an average price target of $18.37. To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.

Exelixis, Inc. (NASDAQ:EXEL) reported financial results for the first quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones. Wall Street analysts, on average, were anticipating just $65.23 million for the quarter.

Beta is also an important valuation ratio for analyzing the stock of the company, EXEL has Beta of 1.9 while its industry and Sector's beta remains at 0.94 and 0.83 respectively. (NASDAQ:EXEL) to Hold in a statement released on 5/03/2017. In the first fiscal quarter of 2016, Exelixis racked up just $15.4 million in revenue. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Michael Morrissey sold 200,000 shares of the firm's stock in a transaction that occurred on Monday, March 6th.

On 3/22/2017 Jeffrey Hessekiel, EVP, sold 23,787 with an average share price of $20.54 per share and the total transaction amounting to $488,584.98. Acrospire Investment Management LLC now owns 16,353 shares of the biotechnology company's stock valued at $209,000 after buying an additional 1,100 shares during the last quarter.

If you are reading this story on another website, it was illegally copied and reposted in violation of worldwide trademark and copyright laws. The shares were sold at an average price of $22.72, for a total value of $4,544,000.00. Trend analysis is based on historical data about the stock's performance given the overall trends of the market and particular indicators within the market. Exelixis's quarterly revenue was up 425.3% compared to the same quarter previous year. If you are viewing this news story on another publication, it was stolen and reposted in violation of USA & global copyright & trademark law. Institutional investors own 78.40% of the company's stock. The disclosure for this sale can be found here.

As the earnings date approaches, we can see that insider ownership is now 1.60% shares, and institutional ownership is at 81.40% for Exelixis, Inc.

While looking at the SMA values of Exelixis, Inc. Laurion Capital Management LP bought a new position in Exelixis during the third quarter worth $208,000.

Latest News